SUMMARY. Target delivery of active pharmaceutical ingredients, including microRNAs, is an urgent problem. Using liposomes as target carriers of different therapeutic agents has some advantages and is becoming more widespread. Liposomes can transport both hydrophilic and hydrophobic molecules at the same time. Liposomes are relatively highly stable under physiological conditions, notable for the regulated release of the encapsulated ingredients, and biocompatible with cell membranes. Medications elaborated based on microRNA encapsulated into liposomes can become an alternative to classic therapeutic agents in treating neurodegenerative diseases. Neuroinflammation is known to be mediated via a complex interaction between the cells of the central nervous system (CNS) and the periphery. Although the inflammatory reaction in the healthy brain is under the strict control of numerous regulatory mechanisms, there may be a deregulation of these processes under pathology. This de-regulation leads to uncontrolled neuroinflammation. Among the main regulators of these processes, a relevant role is played by microRNAs, due to which the processes may become deregulated, promoting the disease progression, or may reflect the homeostatic attempt of the CNS to prevent excessive damage and restore normal conditions of functioning. The study summarizes the literature data about the creation, properties, and utilization of the liposomal form of microRNA, including microRNA-101, in the development of Alzheimer’s disease.
Keywords: neurodegenerative diseases, Alzheimer’s disease, therapeutic agents, microRNA, delivery, liposomes

Full text and supplemented materials
Free full text: PDFReferences
Alles, J., Fehlmann, T., Fischer, U., et al., An estimate of the total number of true human miRNAs, Nucleic Acids Res., 2019, vol. 47, no. 7, pp. 3353–3364. https://doi.org/10.1093/nar/gkz097
Angelucci, F., Cechova, K., Valis, M., et al., MicroRNAs in Alzheimer’s disease: diagnostic markers or therapeutic agents?, Front. Pharmacol., 2019, vol. 10, p. 665. https://doi.org/10.3389/fphar.2019.00665
Bajan, S. and Hutvagner, G., RNA-based therapeutics: from antisense oligonucleotides to miRNAs, Cells, 2020, vol. 9, p. 137. https://doi.org/10.3390/cells9010137
Campbell, K. and Booth, S.A., MicroRNA in neurodegenerative drug discovery: The way forward?, Expert Opin. Drug Discovery, 2015, vol. 10, pp. 9–16. https://doi.org/10.1517/17460441.2015.981254
Chen, J.J., Zhao, B., Zhao, J., et al., Potential roles of exosomal microRNAs as diagnostic biomarkers and therapeutic application in Alzheimer’s disease, Neural Plast., 2017, vol. 2017, p. 7027380. https://doi.org/10.1155/2017/7027380
Chen, J., Qi, Y., Liu, C.F., et al., MicroRNA expression data analysis to identify key miRNAs associated with Alzheimer’s disease, J. Gene Med., 2018, vol. 20, p. e3014. https://doi.org/10.1002/jgm.3014
Christopher, A.F., Kaur, R.P., Kaur, G., et al., MicroRNA therapeutics: Discovering novel targets and developing specific therapy, Perspect. Clin. Res., 2016, vol. 7, no. 2, pp. 68–74. https://doi.org/10.4103/2229-3485.179431
Crew, E., Tessel, M.A., Rahman, S., et al., MicroRNA conjugated gold nanoparticles and cell transfection, Anal. Chem., 2012, vol. 84, pp. 26–29. https://doi.org/10.1021/ac202749p
Cui, X., Song, K., Lu, X., et al., Liposomal delivery of microRNA-7 targeting EGFR to inhibit the growth, invasion, and migration of ovarian cancer, ACS Omega, 2021, vol. 6, no. 17, pp. 11669–11678. https://doi.org/10.1021/acsomega.1c00992
Dasgupta, I. and Chatterjee, A., Recent advances in miRNA delivery systems, Methods Protoc., 2021, vol. 4, no. 1, p. 10. https://doi.org/10.3390/mps4010010
De Felice, B., Guida, M., Guida, M., et al., A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis, Gene, 2012, vol. 508, pp. 35–40. https://doi.org/10.1016/j.gene.2012.07.058
Diener, C., Keller, A., and Meese, E., Emerging concepts of miRNA therapeutics: from cells to clinic, Trends Genet., 2022, vol. 38, no. 6, pp. 613–626. https://doi.org/10.1016/j.tig.2022.02.006
Fang, M., Wang, J., Zhang, X., et al., The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer’s disease, Toxicol. Lett., 2012, vol. 209, pp. 94–105. https://doi.org/10.1016/j.toxlet.2011.11.032
Fromm, B., Domanska, D., Høye, E., et al., MirGeneDB 2.0: the metazoan microRNA complement, Nucleic Acids Res., 2020, vol. 48, no. D1, pp. D132–D141. https://doi.org/10.1093/nar/gkz885
Fu, Y., Chen, J., and Huang, Z., Recent progress in microRNA-based delivery systems for the treatment of human disease, ExRNA, 2019, vol. 1, p. 24. https://doi.org/10.1186/s41544-019-0024-y
Fu, Z., Wang, L., Li, S., et al., MicroRNA as an important target for anticancer drug development, Front. Pharmacol., 2021, vol. 12. https://doi.org/10.3389/fphar.2021.736323
Goldgraben, M.A., Russell, R., Rueda, O.M., et al., Double-stranded microRNA mimics can induce length-and passenger strand-dependent effects in a cell type-specific manner, RNA, 2016, vol. 22, pp. 193–203. https://doi.org/10.1261/rna.054072.115
Hansen, K.F., Sakamoto, K., Aten, S., et al., Targeted deletion of miR-132/-212 impairs memory and alters the hippocampal transcriptome, Learn. Mem., 2016, vol. 23, pp. 61–71. https://doi.org/10.1101/lm.039578.115
He, L. and Hannon, G.J., MicroRNAs: Small RNAs with a big role in gene regulation, Nat. Rev. Genet., 2024, vol. 5, pp. 522–531. https://doi.org/10.1038/nrg1379
Hebert, S.S., Horre, K., Nicolai, L., et al., Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase expression, Proc. Natl. Acad. Sci. U. S. A., 2008, vol. 105, pp. 6415–6420. https://doi.org/10.1073/pnas.0710263105
Ibrahim, A.F., Weirauch, U., Thomas, M., et al., MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma, Cancer Res., 2011, vol. 71, pp. 5214–5224. https://doi.org/10.1158/0008-5472.CAN-10-4645
Khanahmadi, M., Farhud, D.D., and Malmir, M., Genetic of Alzheimer’s disease: A narrative review article, Iran. J. Public Health, 2015, vol. 44, no. 7, pp. 892–901.
Kim, J.H., Yeom, J.H., Ko, J.J., et al., Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles, J. Biotechnol., 2011, vol. 155, pp. 287–292. https://doi.org/10.1016/j.jbiotec.2011.07.014
Kot, K., Kot, Y., Kurbanov, R., et al., The effect of human PBMCs immobilization on their Aβ42 aggregates-dependent proinflammatory state on a cellular model of Alzheimer’s disease, Front. Neurosci., 2024, vol. 18, p. 1325287. https://doi.org/10.3389/fnins.2024.1325287
Kou, X., Chen, D., and Chen, N., The regulation of microRNAs in Alzheimer’s disease, Front. Neurol., 2020, vol. 11, p. 288. https://doi.org/10.3389/fneur.2020.00288
Kovacs, G.G., Molecular pathology of neurodegenerative diseases: principles and practice, J. Clin. Pathol., 2019, vol. 72, pp. 725–735. https://doi.org/10.1136/jclinpath-2019-205952
Kozomara, A., Birgaoanu, M., and Griffiths-Jones, S., miRBase: from microRNA sequences to function, Nucleic Acids Res., 2019, vol. 47, pp. D155–D162. https://doi.org/10.1093/nar/gky1141
Lee, R.C., Feinbaum, R.L., and Ambros, V., The C. elegans heterochronic gene lin‑4 encodes small RNAs with antisense complementarity to lin‑14, Cell, 1993, vol. 75, no. 5, pp. 843–854. https://doi.org/10.1016/0092-8674(93)90529-y
Lee, S.W.L., Paoletti, C., Campisi, M., et al., MicroRNA delivery through nanoparticles, J. Controlled Release, 2019, vol. 313, pp. 80–95. https://doi.org/10.1016/j.jconrel.2019.10.007
Li, J. and Sun, C.K., In vitro analysis of microRNA-26a in chronic lymphocytic leukemia cells, Int. J. Mol. Med., 2018, vol. 42, no. 6, pp. 3364–3370. https://doi.org/10.3892/ijmm.2018.3925
Li, Y.-B., Fu, Q., Guo, M., et al., MicroRNAs: pioneering regulators in Alzheimer’s disease pathogenesis, diagnosis, and therapy, Transl. Psychiatr., 2024, vol. 14, p. 367. https://doi.org/10.1038/s41398-024-03075-8
Lin, H.M., Nikolic, I., Yang, J., et al., MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer, Sci. Rep., 2018, vol. 8, p. 7820. https://doi.org/10.1038/s41598-018-26050-y
Lippi, G., Fernandes, C.C., Ewell, L.A., et al., MicroRNA-101 regulates multiple developmental programs to constrain excitation in adult neural networks, Neuron, 2016, vol. 92, no. 6, pp. 1337–1351. https://doi.org/10.1016/j.neuron.2016.11.017
Liu, C.G., Song, J., Zhang, Y.Q., and Wang, P.C., MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer’s disease, Mol. Med. Rep., 2014, vol. 10, no. 5, pp. 2395–2400. https://doi.org/10.3892/mmr.2014.2484
Liu, Y., Song, Y., and Zhu, X., MicroRNA-181a regulates apoptosis and autophagy process in Parkinson’s disease by inhibiting p38 mitogen-activated protein kinase (MAPK)/c-Jun N-terminal kinases (JNK) signaling pathways, Med. Sci. Monit., 2017, vol. 23, pp. 1597–1606. https://doi.org/10.12659/MSM.900218
Liu, J.-J., Long, Y.-F., Xu, P., et al., Pathogenesis of miR-155 on nonmodifable and modifable risk factors in Alzheimer’s disease, Alzheimer’s Res. Ther., 2023, vol. 15, p. 12. https://doi.org/10.1186/s13195-023-01264-z
Long, J.M. and Lahiri, D.K., MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed, Biochem. Biophys. Res. Commun., 2011, vol. 404, no. 4, pp. 889–895. https://doi.org/10.1016/j.bbrc.2010.12.053
Mercer, T.R., Dinger, M.E., Sunkin, S.M., et al., Specific expression of long noncoding RNAs in the mouse brain, Proc. Natl. Acad. Sci. U. S. A., 2008, vol. 105, no. 2, pp. 716–721. https://doi.org/10.1073/pnas.0706729105
Nguyen, N.T.P., Kumar, M., Fedele, E., et al., MicroRNA alteration, application as biomarkers, and therapeutic approaches in neurodegenerative diseases, Int. J. Mol. Sci., 2022, vol. 23. https://doi.org/10.3390/ijms23094718
Nicoletti, L., Paoletti, C., Tarricone, G., et al., Lipoplexes for effective in vitro delivery of microRNAs to adult human cardiac fibroblasts for perspective direct cardiac cell reprogramming, Nanomedicine, 2022, vol. 45, p. 102589. https://doi.org/10.1016/j.nano.2022.102589
Noren Hooten, N., Abdelmohsen, K., Gorospe, M., et al., microRNA expression patterns reveal differential expression of target genes with age, PLoS One, 2010, vol. 5, p. e10724. https://doi.org/10.1371/journal.pone.0010724
Nsairat, H., Alshaer, W., Odeh, F., et al., Recent advances in using liposomes for delivery of nucleic acid-based therapeutics, OpenNano, 2023, vol. 11, p. 100132. https://doi.org/10.1016/j.onano.2023.100132
Nunez-Iglesias, J., Liu, C.C., Morgan, T.E., et al., Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease cortex reveals altered miRNA regulation, PLoS One, 2010, vol. 5, p. e8898
Pandian, S.R.K., Vijayakumar, K.K., Murugesan, S., and Kunjiappan, S., Liposomes: An emerging carrier for targeting Alzheimer’s and Parkinson’s diseases, Heliyon, 2022, vol. 8, no. 6. https://doi.org/10.1016/j.heliyon.2022.e09575
Parsi, S., Smith, P.Y., Goupil, C., et al., Preclinical evaluation of miR-15/107 family members as multifactorial drug targets for Alzheimer’s disease, Mol. Ther. Nucleic Acids, 2015, vol. 4. https://doi.org/10.1038/mtna.2015.33
Pauley, K.M., Cha, S., and Chan, E.K.L., MicroRNA in autoimmunity and autoimmune diseases, J. Autoimmun., 2009, vol. 32, nos. 3–4, pp. 189–194. HTTPS://DOI.ORG/10.1016/j.jaut.2009.02.012
Shi, Z., Zhang, K., Zhou, H., et al., Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer’s disease, Aging Cell, 2020, vol. 19. https://doi.org/10.1111/acel.13125
Slota, J.A. and Booth, S.A., MicroRNAs in neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications, Non-Coding RNA, 2019, vol. 5, no. 2, p. 35. https://doi.org/10.3390/ncrna5020035
Spizzo, R., Nicoloso, M.S., Croce, C.M., and Calin, G.A., Micro-RNAs in cancer, Cell, 2009, vol. 137, no. 3, pp. 586–586. https://doi.org/10.1016/j.cell.2009.04.040
Sujay, P., Vázquez, L.A.B., Uribe, S.P., et al., Current status of microRNA-based therapeutic approaches in neurodegenerative disorders, Cells, 2020, vol. 9, pp. 1–26. https://doi.org/10.3390/cells9071698
Sun, D., Tan, S., Xiong, Y., et al., MicroRNA biogenesis is enhanced by liposome-encapsulated Pin1 inhibitor in hepatocellular carcinoma, Theranostics, 2019, vol. 9, no. 16, pp. 4704–4716. https://doi.org/10.7150/thno.34588
Taghdiri, M. and Mussolino, C., Viral and non-viral systems to deliver gene therapeutics to clinical targets, Int. J. Mol. Sci., 2024, vol. 25, p. 7333. https://doi.org/10.3390/ijms25137333
Vilardo, E., Barbato, C., Ciotti, M., et al., MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons, J. Biol. Chem., 2010, vol. 285, no. 24, pp. 18344–18351. https://doi.org/10.1074/jbc.M110.112664
Walgrave, H., Zhou, L., De Strooper, B., et al., The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives, Mol. Neurodegener., 2021, vol. 16, p. 76. https://doi.org/10.1186/s13024-021-00496-7
Yamakuchi, M., Ferlito, M., and Lowenstein, C.J., miR-34a repression of SIRT1 regulates apoptosis, Proc. Natl. Acad. Sci. U. S. A., 2008, vol. 105, pp. 13421–13426. https://doi.org/10.1073/pnas.0801613105
Yan, Y., Li, X.Q., Duan, J.L., et al., Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene, Int. J. Nanomed., 2019, vol. 14, pp. 3645–3667. https://doi.org/10.2147/IJN.S207837
Yan, L., Su, Y., Hsia, I., et al., Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment, Mol. Ther. Nucleic Acids, 2023, vol. 32, pp. 36–47. https://doi.org/10.1016/j.omtn.2023.02.031
Yang, N., An overview of viral and nonviral delivery systems for microRNA, Int. J. Pharm. Investig., 2015, vol. 5, no. 4, pp. 179–181. https://doi.org/10.4103/2230-973X.167646
Zhang, B., Chen, C.F., Wang, A.H., and Lin, Q.F., MiR-16 regulates cell death in Alzheimer’s disease by targeting amyloid precursor protein, Eur. Rev. Med. Pharmacol. Sci., 2015, vol. 19, no. 21, pp. 4020–4027.